Cargando…
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
The proto-oncogene RAS, coding for a 21 kDa protein (p21), is mutated in 20% of lung cancer. However, the literature remains controversial on its prognostic significance for survival in lung cancer. We performed a systematic review of the literature with meta-analysis to assess its possible prognost...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361730/ https://www.ncbi.nlm.nih.gov/pubmed/15597105 http://dx.doi.org/10.1038/sj.bjc.6602258 |
_version_ | 1782153285236424704 |
---|---|
author | Mascaux, C Iannino, N Martin, B Paesmans, M Berghmans, T Dusart, M Haller, A Lothaire, P Meert, A-P Noel, S Lafitte, J-J Sculier, J-P |
author_facet | Mascaux, C Iannino, N Martin, B Paesmans, M Berghmans, T Dusart, M Haller, A Lothaire, P Meert, A-P Noel, S Lafitte, J-J Sculier, J-P |
author_sort | Mascaux, C |
collection | PubMed |
description | The proto-oncogene RAS, coding for a 21 kDa protein (p21), is mutated in 20% of lung cancer. However, the literature remains controversial on its prognostic significance for survival in lung cancer. We performed a systematic review of the literature with meta-analysis to assess its possible prognostic value on survival. Published studies on lung cancer assessing prognostic value of RAS mutation or p21 overexpression on survival were identified by an electronic search. After a methodological assessment, we estimated individual hazard ratios (HR) estimating RAS protein alteration or RAS mutation effect on survival and combined them using meta-analytic methods. In total, 53 studies were found eligible, with 10 concerning the same cohorts of patients. Among the 43 remaining studies, the revelation method was immunohistochemistry (IHC) in nine and polymerase chain reaction (PCR) in 34. Results in terms of survival were significantly pejorative, significantly favourable, not significant and not conclusive in 9, 1, 31, 2, respectively. In total, 29 studies were evaluable for meta-analysis but we aggregated only the 28 dealing with non-small-cell lung cancer (NSCLC) and not the only one dealing with small-cell-lung cancer (SCLC). The quality scores were not statistically significantly different between studies with or without significant results in terms of survival, allowing us to perform a quantitative aggregation. The combined HR was 1.35 (95% CI: 1.16–1.56), showing a worse survival for NSCLC with KRAS2 mutations or p21 overexpression and, particularly, in adenocarcinomas (ADC) (HR 1.59; 95% CI 1.26–2.02) and in studies using PCR (HR 1.40; 95% CI 1.18–1.65) but not in studies using IHC (HR 1.08; 95% CI 0.86–1.34). RAS appears to be a pejorative prognostic factor in terms of survival in NSCLC globally, in ADC and when it is studied by PCR. |
format | Text |
id | pubmed-2361730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23617302009-09-10 The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Mascaux, C Iannino, N Martin, B Paesmans, M Berghmans, T Dusart, M Haller, A Lothaire, P Meert, A-P Noel, S Lafitte, J-J Sculier, J-P Br J Cancer Molecular Diagnostics The proto-oncogene RAS, coding for a 21 kDa protein (p21), is mutated in 20% of lung cancer. However, the literature remains controversial on its prognostic significance for survival in lung cancer. We performed a systematic review of the literature with meta-analysis to assess its possible prognostic value on survival. Published studies on lung cancer assessing prognostic value of RAS mutation or p21 overexpression on survival were identified by an electronic search. After a methodological assessment, we estimated individual hazard ratios (HR) estimating RAS protein alteration or RAS mutation effect on survival and combined them using meta-analytic methods. In total, 53 studies were found eligible, with 10 concerning the same cohorts of patients. Among the 43 remaining studies, the revelation method was immunohistochemistry (IHC) in nine and polymerase chain reaction (PCR) in 34. Results in terms of survival were significantly pejorative, significantly favourable, not significant and not conclusive in 9, 1, 31, 2, respectively. In total, 29 studies were evaluable for meta-analysis but we aggregated only the 28 dealing with non-small-cell lung cancer (NSCLC) and not the only one dealing with small-cell-lung cancer (SCLC). The quality scores were not statistically significantly different between studies with or without significant results in terms of survival, allowing us to perform a quantitative aggregation. The combined HR was 1.35 (95% CI: 1.16–1.56), showing a worse survival for NSCLC with KRAS2 mutations or p21 overexpression and, particularly, in adenocarcinomas (ADC) (HR 1.59; 95% CI 1.26–2.02) and in studies using PCR (HR 1.40; 95% CI 1.18–1.65) but not in studies using IHC (HR 1.08; 95% CI 0.86–1.34). RAS appears to be a pejorative prognostic factor in terms of survival in NSCLC globally, in ADC and when it is studied by PCR. Nature Publishing Group 2005-01-17 2004-12-14 /pmc/articles/PMC2361730/ /pubmed/15597105 http://dx.doi.org/10.1038/sj.bjc.6602258 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular Diagnostics Mascaux, C Iannino, N Martin, B Paesmans, M Berghmans, T Dusart, M Haller, A Lothaire, P Meert, A-P Noel, S Lafitte, J-J Sculier, J-P The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis |
title | The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis |
title_full | The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis |
title_fullStr | The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis |
title_full_unstemmed | The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis |
title_short | The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis |
title_sort | role of ras oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361730/ https://www.ncbi.nlm.nih.gov/pubmed/15597105 http://dx.doi.org/10.1038/sj.bjc.6602258 |
work_keys_str_mv | AT mascauxc theroleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT ianninon theroleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT martinb theroleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT paesmansm theroleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT berghmanst theroleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT dusartm theroleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT hallera theroleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT lothairep theroleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT meertap theroleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT noels theroleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT lafittejj theroleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT sculierjp theroleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT mascauxc roleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT ianninon roleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT martinb roleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT paesmansm roleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT berghmanst roleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT dusartm roleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT hallera roleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT lothairep roleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT meertap roleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT noels roleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT lafittejj roleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis AT sculierjp roleofrasoncogeneinsurvivalofpatientswithlungcancerasystematicreviewoftheliteraturewithmetaanalysis |